{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:44:07Z","timestamp":1793727847702,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-024-00789-9","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T06:02:32Z","timestamp":1726120952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database"],"prefix":"10.1186","volume":"25","author":[{"given":"Qing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin-Qin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"789_CR1","unstructured":"Obesity and overweight. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"789_CR2","unstructured":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128\u00b79 million children, adolescents, and adults. Lancet (London England). 2017;390(10113):2627\u201342."},{"key":"789_CR3","unstructured":"World obesity atlas. 2023. https:\/\/data.worldobesity.org\/publications\/?cat=19."},{"key":"789_CR4","doi-asserted-by":"crossref","unstructured":"Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Global Health. 2022;7(9).","DOI":"10.1136\/bmjgh-2022-009773"},{"issue":"3","key":"789_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMra1514009","volume":"376","author":"SB Heymsfield","year":"2017","unstructured":"Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254\u201366.","journal-title":"N Engl J Med"},{"issue":"9793","key":"789_CR6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S0140-6736(11)60813-1","volume":"378","author":"BA Swinburn","year":"2011","unstructured":"Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, Gortmaker SL. The global obesity pandemic: shaped by global drivers and local environments. Lancet (London England). 2011;378(9793):804\u201314.","journal-title":"Lancet (London England)"},{"issue":"5","key":"789_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","volume":"15","author":"M Bl\u00fcher","year":"2019","unstructured":"Bl\u00fcher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288\u201398.","journal-title":"Nat Reviews Endocrinol"},{"issue":"Suppl 2","key":"789_CR8","first-page":"S1","volume":"22","author":"D Ryan","year":"2014","unstructured":"Ryan D, Heaner M. Guidelines (2013) for managing overweight and obesity in adults. Preface to the full report. Obes (Silver Spring Md). 2014;22(Suppl 2):S1\u20133.","journal-title":"Obes (Silver Spring Md)"},{"key":"789_CR9","unstructured":"National Clinical Guideline Centre. National Institute for Health and Care Excellence: guidelines. In: Obesity: identification, assessment and management of overweight and obesity in children, young people and adults: partial update of CG43. edn. London: National Institute for Health and Care Excellence (NICE), National Clinical Guideline Centre; 2014."},{"issue":"6","key":"789_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000370038","volume":"7","author":"G Fr\u00fchbeck","year":"2014","unstructured":"Fr\u00fchbeck G, Toplak H, Woodward E, Halford JC, Yumuk V. Need for a paradigm shift in adult overweight and obesity management - an EASO position statement on a pressing public health, clinical and scientific challenge in Europe. Obes Facts. 2014;7(6):408\u201316.","journal-title":"Obes Facts"},{"issue":"5","key":"789_CR11","doi-asserted-by":"publisher","first-page":"Itc33","DOI":"10.7326\/AITC201903050","volume":"170","author":"AG Tsai","year":"2019","unstructured":"Tsai AG, Bessesen DH. Obesity. Ann Intern Med. 2019;170(5):Itc33\u201348.","journal-title":"Ann Intern Med"},{"key":"789_CR12","doi-asserted-by":"publisher","first-page":"1161521","DOI":"10.3389\/fendo.2023.1161521","volume":"14","author":"R Ruze","year":"2023","unstructured":"Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, Yin X, Xu Q. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:1161521.","journal-title":"Front Endocrinol"},{"key":"789_CR13","doi-asserted-by":"crossref","unstructured":"Alsuhibani A, Thompson JR, Wigle PR, Guo JJ, Lin AC, Rao MB, Hincapie AL. Metabolic and bariatric surgery utilization trends in the United States: evidence from 2012 to 2021 national electronic medical records network %U. Annals Surg Open. 2023;4(4):e317. https:\/\/journals.lww.com\/aosopen\/fulltext\/2023\/12000\/metabolic_and_bariatric_surgery_utilization_trends.28.aspx.","DOI":"10.1097\/AS9.0000000000000317"},{"issue":"9","key":"789_CR14","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1001\/jama.2020.12567","volume":"324","author":"DE Arterburn","year":"2020","unstructured":"Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879\u201387.","journal-title":"JAMA"},{"issue":"7","key":"789_CR15","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/dom.14367","volume":"23","author":"K Suissa","year":"2021","unstructured":"Suissa K, Schneeweiss S, Kim DW, Patorno E. Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States. Diabetes Obes Metab. 2021;23(7):1542\u201351.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"789_CR16","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","volume":"163","author":"E Grunvald","year":"2022","unstructured":"Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, Harindhanavudhi T, Sultan S, Singh S, Davitkov P. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198\u2013225.","journal-title":"Gastroenterology"},{"issue":"3","key":"789_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s13679-019-00350-4","volume":"8","author":"E Nolen-Doerr","year":"2019","unstructured":"Nolen-Doerr E, Stockman MC, Rizo I. Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity. Curr Obes Rep. 2019;8(3):284\u201391.","journal-title":"Curr Obes Rep"},{"issue":"12","key":"789_CR18","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2165\/00003495-200666120-00012","volume":"66","author":"S Henness","year":"2006","unstructured":"Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs. 2006;66(12):1625\u201356.","journal-title":"Drugs"},{"issue":"11","key":"789_CR19","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s40265-015-0427-5","volume":"75","author":"SL Greig","year":"2015","unstructured":"Greig SL, Keating GM. Naltrexone ER\/Bupropion ER: a review in obesity management. Drugs. 2015;75(11):1269\u201380.","journal-title":"Drugs"},{"issue":"8","key":"789_CR20","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1517\/14656566.2015.1041505","volume":"16","author":"N Alfaris","year":"2015","unstructured":"Alfaris N, Minnick AM, Hopkins CM, Berkowitz RI, Wadden TA. Combination phentermine and topiramate extended release in the management of obesity. Expert Opin Pharmacother. 2015;16(8):1263\u201374.","journal-title":"Expert Opin Pharmacother"},{"issue":"15","key":"789_CR21","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1056\/NEJMc2211120","volume":"387","author":"TJA Dekker","year":"2022","unstructured":"Dekker TJA. Tirzepatide once Weekly for the treatment of obesity. N Engl J Med. 2022;387(15):1433.","journal-title":"N Engl J Med"},{"issue":"18","key":"789_CR22","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023;330(18):1795\u20137.","journal-title":"JAMA"},{"issue":"6","key":"789_CR23","doi-asserted-by":"publisher","first-page":"e13435","DOI":"10.1111\/obr.13435","volume":"23","author":"J Iqbal","year":"2022","unstructured":"Iqbal J, Wu HX, Hu N, Zhou YH, Li L, Xiao F, Wang T, Jiang HL, Xu SN, Huang BL, et al. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes Rev Official J Int Association Study Obes. 2022;23(6):e13435.","journal-title":"Obes Reviews: Official J Int Association Study Obes"},{"issue":"1","key":"789_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11096-021-01330-2","volume":"44","author":"A Alsuhibani","year":"2022","unstructured":"Alsuhibani A, Alrasheed M, Gari M, Hincapie AL, Guo JJ. Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA adverse event reporting system (FAERS) databases 2013\u20132020. Int J Clin Pharm. 2022;44(1):172\u20139.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"789_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1208\/s12248-007-9004-5","volume":"10","author":"J Weaver","year":"2008","unstructured":"Weaver J, Willy M, Avigan M. Informatic tools and approaches in postmarketing pharmacovigilance used by FDA. AAPS J. 2008;10(1):35\u201341.","journal-title":"AAPS J"},{"key":"789_CR26","doi-asserted-by":"crossref","unstructured":"Zhou C, Peng S, Lin A, Jiang A, Peng Y, Gu T, Liu Z, Cheng Q, Zhang J, Luo P. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine. 2023;59:101967.","DOI":"10.1016\/j.eclinm.2023.101967"},{"issue":"6","key":"789_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40264-014-0163-x","volume":"37","author":"M Takada","year":"2014","unstructured":"Takada M, Fujimoto M, Yamazaki K, Takamoto M, Hosomi K. Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database. Drug Saf. 2014;37(6):421\u201331.","journal-title":"Drug Saf"},{"issue":"5","key":"789_CR28","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.clgc.2023.07.003","volume":"21","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zhang HM, Jiang Y, Wen Z, Bao EH, Huang J, Wang CJ, Chen CX, Wang JH, Yang XS. Cardiovascular adverse events associated with new-generation androgen receptor pathway inhibitors (ARPI) for prostate Cancer: a disproportionality analysis based on the FDA adverse event reporting System (FAERS). Clin Genitourin Cancer. 2023;21(5):594\u2013601e592.","journal-title":"Clin Genitourin Cancer"},{"key":"789_CR29","unstructured":"Saladin KS, McFarland RK. Human anatomy. Volume 2. McGraw-Hill New York; 2008."},{"key":"789_CR30","doi-asserted-by":"crossref","unstructured":"Park G, Jung H, Heo SJ, Jung I. Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance. Life (Basel Switzerland). 2020;10(8).","DOI":"10.3390\/life10080138"},{"issue":"6","key":"789_CR31","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, et al. The REporting of a disproportionality analysis for DrUg Safety Signal Detection using individual Case Safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47(6):585\u201399.","journal-title":"Drug Saf"},{"key":"789_CR32","doi-asserted-by":"crossref","unstructured":"Subeesh V, Maheswari E, Gr S, Swaroop AM, Minnikanti SS. A comparative study of Data Mining Algorithms used for Signal Detection in FDA AERS Database. J Young Pharmacists. 2018.","DOI":"10.5530\/jyp.2018.10.97"},{"key":"789_CR33","doi-asserted-by":"crossref","unstructured":"Khaleel MA, Khan AH, Ghadzi SMS, Adnan AS, Abdallah QM. A standardized dataset of a spontaneous adverse event reporting system. Healthc (Basel Switzerland). 2022;10(3).","DOI":"10.3390\/healthcare10030420"},{"issue":"6676","key":"789_CR34","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1126\/science.adn4691","volume":"382","author":"J Couzin-Frankel","year":"2023","unstructured":"Couzin-Frankel J. Obesity meets its match. Sci (New York NY). 2023;382(6676):1226\u20137.","journal-title":"Sci (New York NY)"},{"issue":"3","key":"789_CR35","doi-asserted-by":"publisher","first-page":"e13543","DOI":"10.1111\/obr.13543","volume":"24","author":"OS Alkhezi","year":"2023","unstructured":"Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials. Obes Rev Official J Int Assoc Study Obes. 2023;24(3):e13543.","journal-title":"Obes Rev Official J Int Assoc Study Obes"},{"issue":"3","key":"789_CR36","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/dom.12593","volume":"18","author":"MM Smits","year":"2016","unstructured":"Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Cahen DL, van Raalte DH. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab. 2016;18(3):224\u201335.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"789_CR37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","volume":"141","author":"M Elashoff","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150\u20136.","journal-title":"Gastroenterology"},{"issue":"9741","key":"789_CR38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London England). 2010;376(9741):595\u2013605.","journal-title":"Lancet (London England)"},{"issue":"5","key":"789_CR39","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","volume":"21","author":"CM Apovian","year":"2013","unstructured":"Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E. A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obes (Silver Spring Md). 2013;21(5):935\u201343.","journal-title":"Obes (Silver Spring Md)"},{"issue":"5","key":"789_CR40","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1054\/clnu.2002.0565","volume":"21","author":"B Sternby","year":"2002","unstructured":"Sternby B, Hartmann D, Borgstr\u00f6m B, Nilsson A. Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine. Clin Nutr. 2002;21(5):395\u2013402.","journal-title":"Clin Nutr"},{"key":"789_CR41","doi-asserted-by":"publisher","first-page":"113669","DOI":"10.1016\/j.bcp.2019.113669","volume":"170","author":"Y Chen","year":"2019","unstructured":"Chen Y, Zhou J, Xu S, Liu M, Wang M, Ma Y, Zhao M, Wang Z, Guo Y, Zhao L. Association between the perturbation of bile acid homeostasis and valproic acid-induced hepatotoxicity. Biochem Pharmacol. 2019;170:113669.","journal-title":"Biochem Pharmacol"},{"key":"789_CR42","volume-title":"LiverTox: clinical and Research Information on Drug-Induced Liver Injury","author":"Phentermine-Topiramate. In","year":"2012","unstructured":"Phentermine-Topiramate. In. LiverTox: clinical and Research Information on Drug-Induced Liver Injury. edn. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012."},{"issue":"10382","key":"789_CR43","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S0140-6736(22)02403-5","volume":"401","author":"CM Perdomo","year":"2023","unstructured":"Perdomo CM, Cohen RV, Sumithran P, Cl\u00e9ment K, Fr\u00fchbeck G. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet (London England). 2023;401(10382):1116\u201330.","journal-title":"Lancet (London England)"},{"issue":"7","key":"789_CR44","doi-asserted-by":"publisher","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","volume":"11","author":"N Abdel-Wahab","year":"2016","unstructured":"Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events Associated with Immune Checkpoint Blockade in patients with Cancer: a systematic review of Case Reports. PLoS ONE. 2016;11(7):e0160221.","journal-title":"PLoS ONE"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00789-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-024-00789-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00789-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T06:07:29Z","timestamp":1726121249000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-024-00789-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1186\/s40360-024-00789-9","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not provided for this study on human participants because FAERS (FDA Adverse Event Reporting System) is publicly available and anonymous database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}